Ipsen bolsters rare disease pipeline in €700m Memo takeover - Pharmaceutical Technology

Ipsen’s Memo acquisition is the second the former has signed this week alone, following its blockbuster Kartos buyout on 29 June. This is Ipsen’s second acquisition this week, following its blockbuster Kartos buyout on 29 June. Ipsen is acquiring Memo Therapeutics and its anti-BK polyomavirus asset, potravitug to bolster its rare disease pipeline. Credit: Piotr Swat / Shutterstock.com. Ipsen has outlaid €700m ($798.4m) to acquire rare disease specialist Memo Therapeutics – enriching its pipeline with a mid-stage clinical asset. As part of the takeover, the Paris, France-based pharma will pay Memo’s shareholders €200m at transaction close, which is expected in…

Source: Pharmaceutical Technology